Introduction

Living with moderate knee osteoarthritis (OA) can be tough, especially for those hoping to avoid or delay knee replacement surgery. As the condition progresses, pain and stiffness often limit movement, making everyday activities more challenging and impacting quality of life. Recently, there’s been growing interest in treatments that manage symptoms effectively without surgery, allowing people to stay active for longer. Among these options, Arthrosamid has emerged as a promising choice. In this article, we’ll explore how Arthrosamid can act as a “bridge,” helping patients maintain their quality of life, keep working, and continue enjoying hobbies – all while potentially postponing the need for surgery.

What is Arthrosamid? Understanding the Treatment

Arthrosamid is a gel-like substance injected directly into the knee joint. Made from a material called polyacrylamide hydrogel, it acts as a cushion to support and protect the damaged cartilage found in osteoarthritis. By improving lubrication and absorbing shocks inside the joint, Arthrosamid can reduce pain and improve mobility. Unlike surgery, which involves repairing or replacing parts of the joint, this treatment is minimally invasive and focuses on easing symptoms and helping the knee function better.

Arthrosamid sits alongside other non-surgical treatments like physiotherapy and traditional injections, but it offers a unique combination of benefits. It is often recommended for people with moderate OA seeking alternatives to surgery. The treatment is supported by the expertise of Professor Paul Lee, an experienced orthopaedic surgeon, and the patient-centred care at the London Cartilage Clinic. Together, they provide a trustworthy environment for patients considering new treatment avenues.

Arthrosamid as a Bridge Option: Who Stands to Benefit?

If you have moderate knee osteoarthritis and want to manage symptoms without rushing to surgery, Arthrosamid may be a good fit. When we call it a “bridge option,” it means this treatment helps to relieve pain and improve joint function for now, with the aim of delaying more invasive procedures in the future – rather than offering a cure.

Research highlights that Arthrosamid works especially well in certain patient groups. As noted in recent studies, “the intra-articular polyacrylamide hydrogel (PAAG) injection branded Arthrosamid® has been known to be safe and efficacious in knee osteoarthritis (OA) patients.” Furthermore, experts have pointed out there is still much to learn about which patients benefit most, but ongoing studies are helping to clarify who stands to gain the greatest improvements.

For many, Arthrosamid can help ease discomfort enough to stay active, keep working, and continue hobbies that might otherwise be limited by pain. This support for maintaining daily activities plays a huge role in preserving a good quality of life. At the London Cartilage Clinic, Professor Lee and his team provide personalised guidance, helping each patient understand whether this non-surgical pathway suits their individual needs.

How Does Arthrosamid Compare to Other Treatments?

Managing moderate knee OA typically involves a range of non-surgical options like physiotherapy, weight management, and injections such as corticosteroids or hyaluronic acid. While helpful, these sometimes offer only short-term relief or aren’t suited to every patient.

Hyaluronic acid injections are commonly used to postpone surgery, but a large study involving over 30,000 patients found “no significant difference in the likelihood of surgical interventions between low-, moderate-, and high-molecular-weight hyaluronic acid users after accounting for empirically derived confounders” (Shewale et al., 2017). This suggests that the type of hyaluronic acid might not greatly affect if or when surgery becomes necessary.

Arthrosamid, however, is a different kind of treatment that has shown encouraging results for symptom relief and joint function. The London Cartilage Clinic, led by Professor Lee, carefully assesses which patients could benefit most from Arthrosamid, ensuring every treatment plan is tailored to the individual.

One of the practical advantages of Arthrosamid is its potential to help patients stay active, keep working, and enjoy their hobbies for longer — aspects that make a real difference to everyday life.

What Can You Expect from Arthrosamid? Outcomes and Safety

Patients considering Arthrosamid can expect to experience reduced pain and better joint movement, which often leads to an improved quality of life. The treatment is generally well tolerated, especially when delivered by specialists such as Professor Lee and his team at the London Cartilage Clinic.

It’s important to remember that while Arthrosamid can relieve symptoms for many people, it doesn’t cure osteoarthritis or completely halt its progression. Results may vary, and in some cases, surgery may eventually be necessary. Research continues to explore exactly which patients are most likely to benefit from Arthrosamid’s particular approach.

If you’re thinking about Arthrosamid, the best first step is to consult a qualified healthcare professional who can assess your knee condition and discuss the most suitable treatment options.

For individual medical advice, please consult a qualified healthcare professional.

This article provides a clear overview of Arthrosamid as a non-surgical bridge option for moderate knee osteoarthritis, highlighting how it may help improve quality of life and delay surgery under expert care.

References

Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., & Lee, P. Y. (2025). THE IMPACT OF PATIENT FACTORS ON THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE OF ARTHROSAMID POLYACRYLAMIDE HYDROGEL INJECTION FOR KNEE OSTEOARTHRITIS: A COHORT STUDY. Journal of Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2025.02.648

Shewale, A. R., Barnes, C. L., Fischbach, L., Ounpraseuth, S., Painter, J. T., & Martin, B. C. (2017). Comparison of Low-, Moderate-, and High-Molecular-Weight Hyaluronic Acid Injections in Delaying Time to Knee Surgery. The Journal of Arthroplasty, 32(10), 2952-2957.e21. https://doi.org/10.1016/j.arth.2017.04.041